إعلان
إعلان

RAPP

RAPP logo

Rapport Therapeutics, Inc. Common Stock

28.98
USD
برعاية
+0.67
+2.35%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

28.54

-0.44
-1.52%

تقارير أرباح RAPP

النسبة الإيجابية المفاجئة

RAPP تفوق 5 من 6 آخر التقديرات.

83%

التقرير التالي

بيانات التقرير القادم
٠٩ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.67
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-5.63%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
+19.64%

Rapport Therapeutics, Inc. Common Stock earnings per share and revenue

On ٠٦ نوفمبر ٢٠٢٥, RAPP reported earnings of -0.71 USD per share (EPS) for Q3 25, beating the estimate of -0.79 USD, resulting in a 10.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 المحللين forecast an EPS of -0.67 USD, with revenue projected to reach -- USD, implying an نقصان of -5.63% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Rapport Therapeutics, Inc. Common Stock reported EPS of -$0.71, beating estimates by 10.23%, and revenue of $0.00, 0% as expectations.
The stock price moved down -3.1%, changed from $26.17 before the earnings release to $25.36 the day after.
The next earning report is scheduled for ٠٩ مارس ٢٠٢٦.
Based on 11 المحللين, Rapport Therapeutics, Inc. Common Stock is expected to report EPS of -$0.67 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان